NLRP3 Archives -

Only industry-led event on inflammasome-targeted drugs

4th Inflammasome Therapeutics Summit 2022

https://pharmaphorum.com/events/4th-inflammasome-therapeutics-summit-2022/

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus

Novo Nordisk grabs NASH drug from Ventus in $703m deal

https://pharmaphorum.com/news/novo-nordisk-grabs-nash-drug-from-ventus-in-703m-deal/

Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech

Roche bulks up in inflammation with €380m Inflazome acquisition

https://pharmaphorum.com/news/roche-bulks-up-in-inflammation-with-e380m-inflazome-acquisition/

Targeting the Inflammasome

2nd Inflammasome Therapeutics Summit

https://pharmaphorum.com/events/2nd-inflammasome-therapeutics-summit/

NLRP3